E. Ohman J:Or Asset Management Ab Arrowhead Pharmaceuticals, Inc. Transaction History

E. Ohman J:Or Asset Management Ab

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$21.87 - $28.24 $1.62 Million - $2.09 Million	74,046 Added 11.57%	714,206 $18.6 Billion
Q1 2024 May 14, 2024	SELL	$27.21 - $39.48 $46,501 - $67,471	-1,709 Reduced 0.27%	640,160 $18.3 Billion
Q4 2023 Feb 15, 2024	BUY	$21.2 - $31.03 $3.2 Million - $4.68 Million	150,952 Added 30.75%	641,869 $19.6 Billion
Q3 2023 Feb 06, 2024	BUY	$26.2 - $36.08 $12.9 Million - $17.7 Million	490,917 New	490,917 $13.2 Billion
Q2 2023 Apr 05, 2024	BUY	$25.16 - $41.38 $1.09 Million - $1.79 Million	43,200 Added 11.02%	435,317 $15.5 Billion
Q1 2023 Apr 05, 2024	BUY	$23.68 - $38.51 $504,312 - $820,147	21,297 Added 5.74%	392,117 $9.96 Billion
Q4 2022 Apr 05, 2024	BUY	$28.0 - $40.56 $1.93 Million - $2.79 Million	68,900 Added 22.82%	370,820 $15 Billion
Q3 2022 Apr 05, 2024	SELL	$29.63 - $48.31 $10.1 Million - $16.4 Million	-339,949 Reduced 52.96%	301,920 $9.98 Billion

292

90.6M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.